Burjeel Cancer Institute And Avesta Bio Collaborate To Enhance Cancer Research And Treatment Solutions

The Burjeel Cancer Institute (BCI), part of Burjeel Holdings, has entered into a Memorandum of Understanding (MoU) with Avesta Bio, a biotechnology firm from the US. This collaboration aims to enhance cancer research and treatment solutions in the UAE and the surrounding region by combining global expertise.

Under this agreement, both organisations will explore joint clinical research initiatives. They plan to assess the feasibility of conducting multi-phase clinical trials for Avesta Bio’s new investigational therapies. The partnership also aims to strengthen clinical research infrastructure and promote knowledge exchange while developing advanced therapeutic solutions that meet global oncology standards.

Prof. Khaled Musallam, Chief Research Officer at Burjeel Holdings, highlighted the importance of early-stage drug development in building a sustainable research ecosystem in the UAE. He stated that collaborations like this transform the region from being merely consumers of innovation into creators of it.

This partnership supports Abu Dhabi's rise as a global centre for medical innovation and clinical research. It is backed by strong partnerships between healthcare providers, biotechnology companies, and regulatory authorities. The collaboration aligns with the UAE’s national strategy to develop a world-class healthcare ecosystem driven by technology and artificial intelligence.

Prof. Humaid Al Shamsi, CEO of BCI, emphasised that true innovation in cancer care occurs when clinical expertise meets technology-driven intelligence. He noted that this partnership could improve patients’ lives by increasing treatment precision and reducing pain.

Ian Akash Morrison, CEO and Co-Founder of Avesta Bio, expressed pride in bringing their 'Hope Without Harm' mission to life in the UAE's dynamic cancer research ecosystem. He noted that the region offers unique opportunities for biotechnology companies to shape future medicine through bold investments in science, technology, and human talent.

Global Vision for Cancer-Free World

Prof. Sanjay Awasthi, Chairman of the Board and Chief Research Officer at Avesta Bio, shared that expanding their global research footprint is central to their vision of a world free from cancer. Partnering with the UAE allows them to take meaningful steps toward achieving this goal by combining innovation with compassion.

The collaboration between BCI and Avesta Bio represents a significant step towards advancing cancer care in the UAE and beyond. By leveraging cutting-edge technologies and fostering international partnerships, they aim to make substantial progress in cancer treatment and research.

With inputs from WAM